fls.txt



item1.txt
Variable lease payments that depend on an index or a rate are included in the determination of ROU assets and lease liabilities using the index or rate at the lease commencement date, whereas variable lease payments that do not depend on an index or rate are recorded as lease expense in the period incurred.
Amortization expense was $43 million and $129 million, for the quarter and nine months ended September 27, 2019, respectively, and $50 million and $151 million for the quarter and nine months ended September 28, 2018, respectively.
Option periods are included in the lease term if the Company determines that it is reasonably certain the customer will exercise an option.
Intercompany accounts and transactions between consolidated companies have been eliminated in consolidation.
The Company currently expects construction to be completed and to take occupancy of the building by April 1, 2020, at which point the Company's lease agreements for its current corporate headquarters will terminate.
In 2013, the Company received an arbitral award by the International Chamber of Commerce.
An additional sum of over $93 million for costs and pre-judgment interest was subsequently agreed upon pursuant to a court order, bringing the total award to VirnetX in the Apple II case to over $595 million.
The Company's cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less.
The Company has a controlling interest in Mission Support Alliance, LLC ("MSA"), a joint venture with Centerra Group, LLC.
Apple appealed the judgment in the Apple I case with the U.S. Court of Appeals for the Federal Circuit and on January 15, 2019, the court affirmed the $439 million judgment.
The term of the lease is expected to end during fiscal 2036.
In September 2018, the Company terminated its existing interest rate swaps.
Comparative information for the prior fiscal year has not been retrospectively adjusted.
The Company manages its risk to changes in interest rates through the use of derivative instruments.
The Company is a lessor on certain equipment sales-type and operating lease arrangements with its customers.
Financial Statements.
The Company has facilities and equipment lease arrangements.
These swaps are designated as cash flow hedges.
Under the terms of the interest rate swap agreements, the Company will receive monthly variable interest payments based on the one-month LIBOR rate and will pay interest at a fixed rate.
For variable rate borrowings, the Company uses fixed interest rate swaps, effectively converting a portion of the variable interest rate payments to fixed interest rate payments.


item2.txt
The decrease in operating income for the three months ended September 27, 2019, as compared to the three months ended September 28, 2018, was primarily due to increased bad debt expense on certain international contracts and lower net profit write-ups in the current quarter.
For non-defense programs, spending increased to $632 billion in GFY 2020 and $635 billion in GFY 2021.
All were funded at increased levels from the previous year.
We recorded net bookings worth an estimated $5.2 billion and $11.5 billion during the three and nine months ended September 27, 2019, respectively, as compared to $4.6 billion and $10.5 billion for the three and nine months ended September 28, 2018, respectively.
This activity included principal payments on our senior secured term loans of $41 million during the nine months ended September 27, 2019 and $15 million and $46 million during the three and nine months ended September 28, 2018, respectively.
These activities were partially offset by more favorable timing of working capital changes and $59 million received for the Greek arbitration award.
Net cash used in investing activities increased $117 million for the three months ended September 27, 2019, when compared to the prior year quarter, primarily due to $94 million of cash paid related to the acquisition of IMX and $40 million of proceeds received from the settlement of a promissory note in the prior year quarter, partially offset by $12 million of net proceeds received for the divestiture of our health staff augmentation business.


item3.txt



item4.txt
Other Information.


part2.txt
Unregistered Sales of Equity Securities and Use of Proceeds.
Item 1A.


